The Manufacturers Life Insurance Company Purchases Shares of 58,991 Revolution Medicines, Inc. $RVMD

The Manufacturers Life Insurance Company acquired a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, Holdings Channel reports. The firm acquired 58,991 shares of the company’s stock, valued at approximately $11,048,000.

Other hedge funds have also recently made changes to their positions in the company. Nextech Invest Ltd. increased its holdings in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after purchasing an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after purchasing an additional 37,345 shares in the last quarter. Invesco Ltd. increased its position in Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after purchasing an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC raised its stake in Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock valued at $561,000 after purchasing an additional 7,137 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wolfe Research reiterated an “outperform” rating and set a $220.00 price objective on shares of Revolution Medicines in a research report on Monday, August 10th. HC Wainwright increased their price target on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC lifted their price target on Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim boosted their price objective on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wedbush upped their price objective on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $198.89.

Revolution Medicines Price Performance

Shares of RVMD stock opened at $207.88 on Friday. The stock has a 50 day moving average price of $193.33 and a 200 day moving average price of $148.59. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The firm has a market capitalization of $44.56 billion, a P/E ratio of -23.57 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the company earned ($1.31) earnings per share. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -8.85 earnings per share for the current year.

Insider Transactions at Revolution Medicines

In other news, COO Margaret A. Horn sold 60,400 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the transaction, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This trade represents a 27.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at $20,749,870.77. This represents a 13.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 212,497 shares of company stock valued at $38,206,486. Company insiders own 7.60% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.